comparemela.com

All Cohorts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3.

United statesRahul khuranaGeorge lasezkayRemy bernardaJenny kobinDavidm brownClearside biomedical incRetina societyRetina internationalExchange commissionGlobenewswire incSafety profileStable visionReduced frequencyInjections observedClinical trial enrollment

Clearside Biomedical Positive OASIS and Extension Study

- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial.

United statesGeorge lasezkayDavidm brownRemy bernardaRahul khuranaJenny kobinClearside biomedical incExchange commissionRetina societyRetina internationalSafety profileStable visionReduced frequencyInjections observedClinical trial enrollmentData expected

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

ALPHARETTA, Ga., April 27, 2023 Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ,. | April 27, 2023

United statesSouth koreaNew zealandTriamcinolone acetonide suprachoroidalRemy bernardaDennism marcusGeorge lasezkayPeter yuwei changJenny kobinSurgery institutionExchange commissionMd southeast retina centerPreclinical developmentAssociation for researchClearside biomedical incVa physician

Clearside Biomedical Announces Plans for ODYSSEY Phase 2b

- Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga.,.

George lasezkayJenny kobinRemy bernardaExchange commissionClearside biomedical incUs food drug administrationBegin enrollingResults expectedChief executive officerDrug administrationExtension studyTolerability resultsAll cohortsMonth extension studyOptical coherence tomographyNeovascular age related macular degeneration

Clearside Biomedical Announces Positive 6-Month Results

- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders -.

United statesUniversity of arizonaMarkr barakatThomasa ciullaGeorge lasezkayRetinal research instituteUniversity of arizona college medicineClearside biomedical incFavorable safety dataBiologic effect overExtension study participants wentWithout needing additional treatmentParticipants experiencedTreatment burden overConference call todayIncluding key opinion leader

vimarsana © 2020. All Rights Reserved.